Consistent with our findings, Sp1 has been shown to augment the malignant development of CRC through transcriptional activation of long noncoding RNAs.44,45 Our study discovered a novel downstream effector of Sp1 in CRC. The gene discussed is SP1; the disease is colorectal carcinoma.